Department of Molecular Medicine, Pasteur Institute, Cenci-Bolognetti Foundation, University of Rome Sapienza, Rome, Italy.
Stem Cell Rev Rep. 2011 Nov;7(4):1018-30. doi: 10.1007/s12015-011-9252-8.
Heart failure remains one of the main causes of morbidity and mortality in the Western world. Current therapies for myocardial infarction are mostly aimed at blocking the progression of the disease, preventing detrimental cardiac remodeling and potentiating the function of the surviving tissue. In the last decade, great interest has arisen from the possibility to regenerate lost tissue by using cells as a therapeutic tool. Different cell types have been tested in animal models, including bone marrow-derived cells, myoblasts, endogenous cardiac stem cells, embryonic cells and induced pluripotent stem cells. After the conflicting and often inconsistent results of the first clinical trials, a step backward needs to be performed, to understand the basic biological mechanisms underlying spontaneous and induced cardiac regeneration. Current studies aim at finding new strategies to enhance cellular homing, survival and differentiation in order to improve the overall outcome of cellular cardiomyoplasty.
心力衰竭仍然是西方世界发病率和死亡率的主要原因之一。目前治疗心肌梗死的方法主要是阻止疾病的进展，防止有害的心脏重构，并增强存活组织的功能。在过去的十年中，人们对使用细胞作为治疗工具来再生丢失组织的可能性产生了浓厚的兴趣。不同类型的细胞已在动物模型中进行了测试，包括骨髓来源的细胞、成肌细胞、内源性心脏干细胞、胚胎细胞和诱导多能干细胞。在第一批临床试验的结果相互矛盾且常常不一致之后，需要退一步，以了解自发和诱导性心脏再生的基本生物学机制。目前的研究旨在寻找新的策略来增强细胞归巢、存活和分化，以提高细胞心肌成形术的整体效果。
